CTRP9 Mitigates the Progression of Arteriovenous Shunt-Induced Pulmonary Artery Hypertension in Rats

Figure 2

PAH is prevented and attenuated by the administration of CTRP9. (a) The rats in the shunt group exhibited a significantly higher mPAP compared with that of the rats in the sham group at the end of the 12^th week. (b) The rats in the shunt group exhibited a significantly higher RVSP compared with that of the rats in the sham group at the end of the 12^th week. (c) Quantification of the percentage of wall thickness to vessel diameter. (d) Quantification of the lumen area to vessel total area. (e) Representative images of H&E-stained resistant pulmonary arteries from the different experimental groups. of each group. . and vs. the Ad-GFP-sham group. PAH: pulmonary arterial hypertension; CTRP9: C1q/TNF-related protein 9; mPAP: mean pulmonary artery pressure; RVSP: right ventricular systolic pressure; H&E: hematoxylin and eosin; Ad-GFP: adenovirus-green fluorescent protein.

(a)

(b)

(c)

(d)

(e)